Chemical chaperones: mechanisms of action and potential use.
暂无分享,去创建一个
[1] L N Csonka,et al. Physiological and genetic responses of bacteria to osmotic stress. , 1989, Microbiological reviews.
[2] Matthew P. Anderson,et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.
[3] W. Crowley,et al. Male hypogonadotropic hypogonadism. , 1993, Endocrinology and metabolism clinics of North America.
[4] D. Clarke,et al. Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. , 1994, The Journal of biological chemistry.
[5] Satoshi Ishii,et al. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease , 1995 .
[6] S. Brusilow,et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. , 1995, Blood.
[7] D. Clarke,et al. P-glycoprotein , 1995, The Journal of Biological Chemistry.
[8] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[9] William J. Welch,et al. Influence of molecular and chemical chaperones on protein folding. , 1996, Cell stress & chaperones.
[10] A S Verkman,et al. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. , 1996, Cell stress & chaperones.
[11] J. Wine,et al. Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.
[12] W. Welch,et al. Correcting temperature-sensitive protein folding defects. , 1997, The Journal of clinical investigation.
[13] D. Bichet,et al. Nephrogenic diabetes insipidus. , 2001, Annual review of physiology.
[14] S. Gellman,et al. Artificial Chaperone-assisted Refolding of Citrate Synthase* , 1998, The Journal of Biological Chemistry.
[15] E. Bertram,et al. Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo. , 1998, Journal of immunology.
[16] A. Verkman,et al. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. , 1998, The Journal of clinical investigation.
[17] L. Whitesell,et al. Molecular chaperones: biology and prospects for pharmacological intervention. , 1998, Pharmacological reviews.
[18] K. Kirk,et al. Activation of DeltaF508 CFTR in an epithelial monolayer. , 1998, The American journal of physiology.
[19] S. Kaler. Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. , 1998, The American journal of clinical nutrition.
[20] A S Verkman,et al. Misfolding of Mutant Aquaporin-2 Water Channels in Nephrogenic Diabetes Insipidus* , 1999, The Journal of Biological Chemistry.
[21] B. Foster,et al. Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.
[22] I. Baskakov,et al. Trimethylamine N-Oxide-induced Cooperative Folding of an Intrinsically Unfolded Transcription-activating Fragment of Human Glucocorticoid Receptor* , 1999, The Journal of Biological Chemistry.
[23] D. Clarke,et al. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. , 1999, Biochimica et biophysica acta.
[24] P. Fraser,et al. Manipulating the Amyloid-β Aggregation Pathway with Chemical Chaperones* , 1999, The Journal of Biological Chemistry.
[25] C. January,et al. Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome , 1999, The Journal of Biological Chemistry.
[26] Satoshi Ishii,et al. Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.
[27] R. Kopito,et al. Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.
[28] T. Wisniewski,et al. Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.
[29] D. Perlmutter,et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Bichet,et al. Pharmacological chaperones: a new twist on receptor folding. , 2000, Trends in pharmacological sciences.
[31] S. Angers,et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.
[32] C. Partridge,et al. Identification and Pharmacological Correction of a Membrane Trafficking Defect Associated with a Mutation in the Sulfonylurea Receptor Causing Familial Hyperinsulinism* , 2001, The Journal of Biological Chemistry.
[33] F E Cohen,et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] L. Galietta,et al. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. , 2001, Journal of cell science.
[35] D. Chuang,et al. Natural Osmolyte Trimethylamine N-Oxide Corrects Assembly Defects of Mutant Branched-chain α-Ketoacid Decarboxylase in Maple Syrup Urine Disease* , 2001, The Journal of Biological Chemistry.
[36] A S Verkman,et al. Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds* 210 , 2001, The Journal of Biological Chemistry.
[37] P. Goloubinoff,et al. Chemical Chaperones Regulate Molecular Chaperones in Vitro and in Cells under Combined Salt and Heat Stresses* , 2001, The Journal of Biological Chemistry.
[38] G. Wiens,et al. Recovering Antibody Secretion Using a Hapten Ligand as a Chemical Chaperone* , 2001, The Journal of Biological Chemistry.
[39] M. K. Chattopadhyay,et al. Chaperone-like properties of lysophospholipids. , 2001, Biochemical and biophysical research communications.
[40] Robert J. Desnick,et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.
[41] M. Boyle,et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[42] R. Rudolph,et al. The non‐ionic detergent Brij 58P mimics chaperone effects , 2002, FEBS letters.
[43] Protein origami: therapeutic rescue of misfolded gene products. , 2002, Molecular interventions.
[44] Jussi Taipale,et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. , 2002, Genes & development.
[45] P. Conn,et al. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. , 2002, The Journal of clinical endocrinology and metabolism.
[46] Byung-Eun Kim,et al. A Conditional Mutation Affecting Localization of the Menkes Disease Copper ATPase , 2002, The Journal of Biological Chemistry.
[47] M. Bouvier,et al. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation , 2002, The EMBO journal.
[48] Ernest Beutler,et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] I. Kanazawa,et al. Chemical Chaperones Reduce Aggregate Formation and Cell Death Caused by the Truncated Machado–Joseph Disease Gene Product with an Expanded Polyglutamine Stretch , 2002, Neurobiology of Disease.
[50] C. Hollak,et al. Gaucher disease: from fundamental research to effective therapeutic interventions. , 2003, The Netherlands journal of medicine.
[51] W. El-Deiry,et al. Restoring p53-Dependent Tumor Suppression , 2003, Cancer biology & therapy.
[52] Fred E. Cohen,et al. Therapeutic approaches to protein-misfolding diseases , 2003, Nature.
[53] Xinbin Chen,et al. Isolation and Characterization of Fourteen Novel Putative and Nine Known Target Genes of the p53 Family , 2003, Cancer biology & therapy.
[54] D. Selkoe. Folding proteins in fatal ways , 2003, Nature.
[55] I. Braakman,et al. Quality control in the endoplasmic reticulum protein factory , 2003, Nature.
[56] Claudio Soto,et al. Unfolding the role of protein misfolding in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.
[57] O. Chilson,et al. Perturbation of folding and reassociation of lactate dehydrogenase by proline and trimethylamine oxide. , 2003, European journal of biochemistry.
[58] Christopher M. Tan,et al. Appropriate Polarization following Pharmacological Rescue of V2 Vasopressin Receptors Encoded by X-linked Nephrogenic Diabetes Insipidus Alleles Involves a Conformation of the Receptor That Also Attains Mature Glycosylation* , 2003, Journal of Biological Chemistry.
[59] H. Takagi,et al. Gene Dosage Effect of l-Proline Biosynthetic Enzymes on l-Proline Accumulation and Freeze Tolerance in Saccharomyces cerevisiae , 2003, Applied and Environmental Microbiology.
[60] A. Fersht,et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[61] Seiichiro Ogawa,et al. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[62] R. Stockley,et al. α1-Antitrypsin deficiency • 3: Clinical manifestations and natural history , 2004, Thorax.
[63] Neena Singh,et al. Doxycycline and protein folding agents rescue the abnormal phenotype of familial CJD H187R in a cell model. , 2004, Brain research. Molecular brain research.
[64] Michel Bouvier,et al. Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.
[65] L. Cebotaru,et al. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. , 2004, Physiological genomics.
[66] A. Fersht,et al. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". , 2004, Journal of molecular biology.
[67] Y. Nomura,et al. Sodium 4-Phenylbutyrate Protects against Cerebral Ischemic Injury , 2004, Molecular Pharmacology.
[68] S. Shyng,et al. Sulfonylureas Correct Trafficking Defects of ATP-sensitive Potassium Channels Caused by Mutations in the Sulfonylurea Receptor* , 2004, Journal of Biological Chemistry.
[69] I. Goldenberg,et al. Long QT syndrome. , 2008, Journal of the American College of Cardiology.